HTB | HIV i-Base

HTB

AIDS 2020: weight change with integrase inhibitors and TAF; COVID-19 and HIV, new treatment and vaccines...

Featured HTB: no. 10 – HIV and COVID-19: issue 7 (28 August 2020) 28 August 2020. Related: Editorial.
Featured i-Base appeal: please support i-Base with £5 or £10 a month 28 August 2020. Related: Editorial.
Featured HTB: no. 9 – HIV and COVID-19: issue 6 (22 July 2020) 22 July 2020. Related: Editorial.
Featured HTB 17 April 2020: CROI 2020 and COVID-19 supplement 17 April 2020. Related: Editorial.
Featured Impact of isolation and loneliness on older people living with HIV 13 December 2019. Related: Conference reports, Ageing and life expectancy, HIV and Ageing 2019.
Featured The evidence for U=U (Undetectable = Untransmittable): why negligible risk is zero risk 1 October 2017. Related: Special reports, HIV prevention and transmission.
COVID-19 deaths in children and people <21 years old in the US 16 September 2020. Related: Early access, COVID-19: paediatrics, COVID-19.
IDSA guidelines on serologic testing for SARS-CoV-2 16 September 2020. Related: Early access, COVID-19: diagnostics, COVID-19.
US study of HIV positive people with COVID-19 reports worse outcomes with comorbidities and having a CD4 <200 11 September 2020. Related: Early access, COVID-19: HIV and COVID-19 coinfection, COVID-19.
Tocilizumab fails to meet clinical endpoints in randomised COVACTA study: other studies continue 9 September 2020. Related: Early access, COVID-19: investigational drugs, COVID-19.
New insights into elite control of HIV and a possible case of virus clearance 29 August 2020. Related: Early access, Cure research.
23rd International AIDS Conference (AIDS 2020): second reports 28 August 2020. Related: Conference reports, Conference index, World AIDS 23 Virtual 2020.
Capsid inhibitor lenacapavir (GS-6207) allows for 6-monthly dosing 28 August 2020. Related: Conference reports, Antiretrovirals, World AIDS 23 Virtual 2020.
Weight gain with integrase inhibitors and TAF: three reports from AIDS 2020 28 August 2020. Related: Conference reports, Side effects, World AIDS 23 Virtual 2020.
Dolutegravir non-inferior to efavirenz at week 96 in the NAMSAL study but associated with substantial weight gain 28 August 2020. Related: Conference reports, Treatment strategies, World AIDS 23 Virtual 2020.
Switching from efavirenz- to dolutegravir-based ART second-line achieved good rates of suppression: first results from the VISEND study 28 August 2020. Related: Conference reports, Treatment strategies, World AIDS 23 Virtual 2020.
Paediatric dolutegravir dosing at AIDS 2020 28 August 2020. Related: Conference reports, Paediatric care, World AIDS 23 Virtual 2020.
COVID-19 outcomes in HIV positive people in two large US cohorts 28 August 2020. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19, World AIDS 23 Virtual 2020.
AIDS 2020: virtual content now available free and on-demand 28 August 2020. Related: Conference reports, Other news, World AIDS 23 Virtual 2020.
Pathways to an HIV cure: online presentations 28 August 2020. Related: Conference reports, Cure research, World AIDS 23 Virtual 2020, IAS Cure 2020.
US FDA approves dolutegravir/lamivudine (Dovato) as switch option 28 August 2020. Related: Antiretrovirals.
EMA extends indication for darunavir/r to include adolescents >12 years 28 August 2020. Related: Antiretrovirals.
ViiV resubmits cabotegravir plus rilpivirine long-acting injections (Cabenuva) to FDA for approval 28 August 2020. Related: Antiretrovirals.
EMA supports use of dapivirine vaginal ring to prevent HIV in high-incidence countries 28 August 2020. Related: HIV prevention and transmission.
HIV organisations challenge government proposal to abolish Public Health England 28 August 2020. Related: Other news.
Modern ART – community video 28 August 2020. Related: On the web.
AVAC web interviews about new treatments to prevent HIV 28 August 2020. Related: On the web.
HIV associated with worse outcomes from COVID-19 in UK ISARIC and OpenSAFELY databases 28 August 2020. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
European and UK doctors review latest studies on HIV and COVID-19 coinfection 28 August 2020. Related: COVID-19: HIV and COVID-19 coinfection, COVID-19.
Tocilizumab associated with better outcomes from COVID-19 in US study 28 August 2020. Related: COVID-19: investigational drugs, COVID-19.
Famotidine associated with better outcomes from COVID-19 28 August 2020. Related: COVID-19: investigational drugs, COVID-19.
INSIGHT network to study monoclonal antibodies for COVID-19 including LY-CoV555 28 August 2020. Related: COVID-19: investigational drugs, COVID-19.
US activists ensure people living with HIV can enrol in COVID-19 vaccine studies 28 August 2020. Related: COVID-19: vaccine, COVID-19.
HIV organisations oppose active-challenge COVID-19 vaccine studies 28 August 2020. Related: COVID-19: vaccine, COVID-19.
AVAC webinar with Barney Graham: COVID-19 vaccine targets, timelines, efficacy and ethical issues 28 August 2020. Related: COVID-19: vaccine, COVID-19.
Equitable access to vaccines against COVID-19 28 August 2020. Related: COVID-19: vaccine, COVID-19.
Future meetings 2020/21 28 August 2020. Related: Future meetings.
HTB no 10 – plus: HIV and COVID-19 bulletin no 7 (28 August 2020) 28 August 2020. Related: PDFs.
IAS COVID-19 Conference: introduction 22 July 2020. Related: Conference reports, Conference index, IAS COVID-19 virtual 2020.
Conference opening and making sense of the science 22 July 2020. Related: Conference reports, COVID-19, IAS COVID-19 virtual 2020.
HepC drugs for COVID-19: sofosbuvir/daclatasvir show faster recovery and reduced mortality 22 July 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19, IAS COVID-19 virtual 2020.
Predictors of response to remdesivir in GS-5773 COVID-19 study 22 July 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19, IAS COVID-19 virtual 2020.
AIDS 2020 online: introduction 22 July 2020. Related: Conference reports, Conference index, World AIDS 23 Virtual 2020.
AIDS 2020: Navigating the website 22 July 2020. Related: Conference reports, World AIDS 23 Virtual 2020.
Neural tube defects in two of 1000 conception exposures with dolutegravir: reassuring update from Tsepamo study 22 July 2020. Related: Conference reports, Pregnancy, World AIDS 23 Virtual 2020.
Dolutegravir associated with weight gain in African ART programmes: findings from AFRICOS 22 July 2020. Related: Conference reports, Side effects, World AIDS 23 Virtual 2020.
ADVANCE 96-week results: dolutegravir weight gain continues, especially in women and when used with TAF – no evidence of a plateau 22 July 2020. Related: Conference reports, Antiretrovirals, World AIDS 23 Virtual 2020.
Obesity linked to dolutegravir, especially with TAF, could increase risk of adverse pregnancy outcomes 22 July 2020. Related: Conference reports, Women's health, Pregnancy, Side effects.
Pregnancy meta-analysis: dolutegravir- versus efavirenz-based ART 22 July 2020. Related: Conference reports, Pregnancy, World AIDS 23 Virtual 2020.
Long-acting cabotegravir injections are effective as HIV PrEP in gay men and transgender women: results from HPTN 083 22 July 2020. Related: Conference reports, HIV prevention and transmission, World AIDS 23 Virtual 2020.
Case report of short-term HIV remission from adding oral nicotinamide to intensified ART 22 July 2020. Related: Conference reports, Cure research, World AIDS 23 Virtual 2020.
New HIV remission case report at AIDS 2020: full report 22 July 2020. Related: Conference reports, Cure research, World AIDS 23 Virtual 2020.
FDA approves fostemsavir (Rukobia) for multidrug resistant HIV in the US 22 July 2020. Related: Antiretrovirals.